Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis
(WorldNews France)

September 14, 2020 Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis Caelum Biosciences, a company founded by Fortress, is collaborating with Alexion Pharmaceuticals on the studies Phase 2 study met primary objective,supporting initiation of two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrate prolonged overall survival (78 percent at 37 months) and durable organ response NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative revenue-generating company...